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MicroRNAs (miRNAs) in Neurodegenerative Diseases
Peter T. Nelson1,2,*, Wang-Xia Wang1,2,*, and Bernard W. Rajeev1,2,*
1 Sanders-Brown Center on Aging, University of Kentucky, Lexington, Ky
2 Department of Pathology, University of Kentucky, Lexington, Ky
Abstract
Aging-related neurodegenerative diseases (NDs) are the culmination of many different genetic and
environmental influences. Prior studies have shown that RNAs are pathologically altered during
the inexorable course of some NDs. Recent evidence suggests that microRNAs (miRNAs) may be
a contributing factor in neurodegeneration. miRNAs are brain-enriched, small (~22 nucleotides)
non-coding RNAs that participate in mRNA translational regulation. Although discovered in the
framework of worm development, miRNAs are now appreciated to play a dynamic role in many
mammalian brain-related biochemical pathways, including neuroplasticity and stress responses.
Research about miRNAs in the context of neurodegeneration is accumulating rapidly, and the goal
of this review is to provide perspective for these new data that may be helpful to specialists in
either field. An overview is provided about the normal functions for miRNAs, including some of
the newer concepts related to the human brain. Recently published studies pertaining to the roles
of miRNAs in NDs––including Alzheimer’s disease, Parkinson’s disease and triplet repeat
disorders—are described. Finally, a discussion is included with theoretical syntheses and possible
future directions in exploring the nexus between miRNA and ND research.
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INTRODUCTION: PERTINENT GENERAL ASPECTS OF
NEURODEGENERATIVE DISEASES
“Neurodegeneration” is a term that has been used to refer to differing topics. Abundant
nerve cell death occurs in the course of normal brain development, and many pediatric
neurological diseases are characterized by pathological degeneration of neurons and/or
muscles. Phenomena involving nerve cell death also occur in animal models and cells in
culture. This review is focused upon the human-specific neurodegenerative diseases (NDs)
that afflict mainly the elderly, particularly trinucleotide repeat diseases, Alzheimer’s disease
(AD) and the synucleinopathies, such as Parkinson’s disease (PD).
In the course of NDs, neurons lose their connections and die prematurely. Although highly
relevant to “physiological” cell death, the role of apoptosis in most NDs has not been
conclusively proven, and will not be discussed here in great detail. Each noso-logical ND
entity has its own set of pathological processes, some of which are presumably unique.
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However, there are six general ideas that are relevant at least circumstantially to how
microRNA (miRNA) biochemistry may interact with the pathogenesis of NDs.
(i) Most NDs are not inherited in patterns that reflect simple Mendelian genetics
Most prevalent subtypes of NDs, such as AD and PD, are inherited in a manner termed
“sporadic” (as opposed to “familial”), influenced by alleles with limited genetic penetrance,
or are caused by genetic and/or environmental influences as yet uncharacterized (28,102).
These facts may shift the focus of ND genetic studies away from “traditional” genes which
constitute only ~1%–2% of human DNA, and towards the other ~50% of transcribed DNA
about which we are mostly ignorant (48,96).
(ii) Brains of human ND patients show evidence of chronic stress
ND brains show evidence of considerable cellular stress (77,105). Although this may be
expected in disease processes that last for long periods and involve abundant cell death, this
response may prove contributory because the stress response itself could play a role in the
“cascade” effect (see below) that result ultimately in neurological deficits.
(iii) NDs may be exacerbated in the clinicobiological sense by the aberrant stimuli of
developmental pathways
Some biochemical pathways that are up-regulated during normal brain development, but
down-regulated in normal adulthood, are then aberrantly up-regulated again in the course of
NDs. These include pathways involved in cell–cell signaling, cell division, neuroplasticity
and apoptosis (see reviews 3, 17, 91). In the case of the microtubule-associated protein tau
(MAPT), there is an mRNA splicing variant that is more highly represented both in early
development and in some neurodegenerative diseases (57,88). Furthermore, the
developmentally up-regulated phosphorylation of MAPT is also up-regulated in AD
neurofibrillary pathology (39,119). These are only a few examples of how the up-regulation
of developmental pathways in the adult milieu may contribute to the pathological
progression of some NDs.
(iv) RNA is pathologically altered in NDs
RNA biochemists are well aware that RNA is labile in even tightly controlled
circumstances. In the course of some NDs, brain RNAs becomes pathologically altered.
These changes have been reviewed elsewhere (81,88,118), but include aberrant RNA
oxidation, RNA degradation, altered RNA splicing and ribosomal changes which cause
mRNA translational frame-shifting abnormalities.
(v) Human NDs are chronic conditions that last for decades rather than just for several
years
Recent studies have established the surprising chronicity of the processes underlying NDs.
Using AD as an example, the time from patients’ clinical diagnosis to death is typically ~8
years (126). However, the underlying pathological processes of AD occur over many
decades. Persons at risk for developing AD in their seventh or eighth decade already show
brain metabolic abnormalities by PET scan even in their third decade of life (103,112).
These are important data because they show that ND pathology involves a long-evolving
shift in cellular equilibrium, which could be “tipped” even by subtle genetic and/or
environmental influences.
(vi) Pathogenetic mechanisms of ND involve multiple distinct steps
Most NDs are probably not just a “one-hit” phenomenon, but rather they probably involve a
sequential progression of pathological processes that result collectively in neuronal death
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and/or compromised connectivity. In the case of AD, the most prevalent hypothesis is the
“amyloid cascade hypothesis” (43,44), and both neuritic amyloid plaques and neurofibrillary
tangles are apparently required to produce the advanced clinical stages of the disease (as
described in 129).
These six features of NDs dovetail on some of the known characteristics of miRNA
biochemistry in the brain. As described below, miRNAs derive from “non-traditional
genes”; are related to pathways of cellular stress and neurodevelopment; may be altered by
the changes seen in ND brains such as oxidation; and may ultimately contribute to step(s)
that culminate in chronic brain diseases.
INTRODUCTION: GENERAL ASPECTS ABOUT TRANSCRIPTIONAL
REGULATION AND miRNAs
In mammalian cells, mRNA levels and protein levels tend to correlate quite poorly (88).
This may be because translation (RNA→Protein) is even more important than transcription
(DNA→RNA) as a nidus for gene expression regulation. More than 95% of human cellular
RNAs are “non-coding” RNAs, that is, other than mRNA, and most of these molecules
participate in translational regulation (48,96). These and other data have led researchers to
seek a better understanding of mRNA translation.
miRNAs are small non-coding RNAs with potent biological activities involved in mRNA
translational regulation (see Figure 1). Derived from genes that reside between or within
protein-coding genes, miRNAs may be transcribed by RNA polymerase II (usually) or by
RNA polymerase III (16,19,66). The precursor RNAs are processed endonucleolytically and
exported to the cytoplasm where they are further trimmed by dicer protein to their mature
form (89). These “mature”, short (~22 nucleotides in length), single-stranded miRNAs are
bound intimately to argonaute proteins, which apparently mediate miRNAs’ ultimate
functions (20,42). Argonaute proteins and miRNA biochemical machinery are universal
among eukaryotes, but great diversity is evident in the particular characteristics of miRNA
functions in vivo. The canonical function of argonaute-bound miRNAs is the suppression of
target mRNAs. In other words, an mRNA that is “targeted” by miRNAs may be present by a
cDNA microarray experiment, reverse transcriptase PCR, Northern blot or other “expression
profiling” technique; however, there would be little or no polypeptide deriving from that
mRNA.
Biochemical mechanisms by which miRNAs work are probably numerous depending on the
availability of local regulatory factors (see for example 53, 60, 67, 95, 97). miRNAs are a
relatively recent discovery, having been first recognized in animals in the context of worm
development. In the Caenorhabditis elegans heterochronic pathway, miRNAs participate in
the sequential process of cell fate determination by decreasing the production of certain
proteins despite high levels of their cognate mRNAs (36,65,104). This system provides one
contextual paradigm for miRNA action, in which a “one miRNA, one/few mRNA target(s)”
rule seems to apply in a set developmental staging schema. However, the characteristics of
miRNA-related biochemical pathways have provided many surprises, and more are no doubt
yet to come.
129 Nelson PT, Jicha GA, Schmitt FA, Liu HL, Davis DG, et al. Clinicopathological Correlations in a Large Alzheimer’s Disease
Center Autopsy Cohort: Neuritic Plaques and Neurofibrillary Tangles “Do Count” When Staging Disease Severity. J Neuropathol Exp
Neurol. in press.
After submission of the manuscript, excellent additional work of miRNAs up-regulated targeted mRNAs was published by the
laboratory of Joan Steitz.
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One unexpected characteristic of some human miRNAs is their very high RNA copy number
per cell. Particular miRNAs can be represented by 1000–30 000 copies per cell or more
(1,72). By comparison, the large majority of mRNAs typically number less than 100 copies
per cell (21,115).
If miRNAs participate in gene expression regulation and are represented in high numbers
per cell, how extensive is the cellular impact of miRNAs? Numerous studies have now
established that miRNAs can have a profound cellular impact by dint of sheer biochemical
promiscuity: each miRNA can regulate hundreds, thousands or more mRNA targets. This
was first indicated by predictive bioinformatics, which showed that evolutionarily conserved
“miRNA recognition elements” are present in the 3′ untranslated region (3′UTR) of very
many mRNAs per miRNA (7,38,56,59,69,70,83). Further studies have exploited the fact that
in some circumstances, miRNAs actually cause down-regulation of target mRNA, in
addition to protein, so that cDNA microarrays could be compared between functionally
miRNA-transfected cells and controls (41,73,75,124). These studies have shown
convincingly that each miRNA can regulate thousands of different mRNA targets. Hence,
these small non-coding RNAs, which are present in very high gene copy numbers and which
work through a powerful translational regulation paradigm, can modify an exceptionally
large number of genes.
Recent studies have revealed intriguing novel aspects of miRNA function (see Figure 2):
• Some miRNAs are edited post-transcriptionally, and thus their targets can be
profoundly altered (15,76,93).
• Some human miRNAs are targeted to the nucleus for as yet unknown reasons (49).
• miRNAs are shown to alter mRNA splicing and/or DNA methylation in trans
(14,18,34,80).
• miRNAs (like siRNAs) may recognize mRNAs outside of the 3′UTR, opening up
new possibilities for complex gene expression regulation (84).
• Viral-derived miRNAs/siRNAs can play important roles in host cell biochemistry
(23,30,111).
• Under some circumstances, miRNAs can increase translation of targeted mRNAs
(10,11,47). See note added in proof at end of article.
• Numerous cell- and organism-level functions as diverse as immunomodulation
(26,27,108), endocrine function (29,101,109), circadian rhythms (24,92), metabolic
pathways (125), limb morphogenesis (45) and angiogenesis (63,100,120,128) have
been hypothesized to be regulated by miRNAs.
miRNAs IN CELLULAR STRESS
As mentioned above, cellular stress is a conspicuous feature of ND brains. A detailed
catalog of the many roles now thought to be played by miRNAs in stress is beyond the scope
of this review. However, miRNAs’ expressions have been shown to change dramatically in
response to cold and heat stress, hypoxia, oxidative stressors, arsenic, irradiation, nutrient
deprivation and other stresses (2,25,32,51,79,82,107,110,121). Typically, in stress
conditions, a subset of miRNAs are increased, and a subset are decreased. The subset of
miRNAs that are altered in one stress condition and in one cell type are not necessarily
related to the miRNAs which change expression upon a different stressful stimulus. To
illustrate the point, miR-93 is up-regulated in titanium-induced stress in a human osteoblast
cell line and in the liver of chronically tamoxifen-fed rats, but down-regulated in hypoxic
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human trophoblasts; however, miR-93 showed no evident expression change in folate
deficiency or arsenic exposure in a lymphoblastic cell line (31,82,94,99).
The biochemical effects of miRNAs during cellular stress can change dramatically. For
example, stress may alter a miRNA: m-RNA interaction to produce translational up-
regulation of target mRNAs (10,11,47), which is the opposite of “canonical” miRNA
activity. This has prompted speculation that miRNAs may constitute a “safeguard against
turmoil”, by altering globally the parameters of translational machinery in the cells during
stress (68). Plant miRNAs also participate in the stress response in part through a ubiquitin
pathway (5,25); this is intriguing partly because plant miRNA paradigms have been
fundamentally important in understanding the anciently evolved miRNA pathways. In
summary, during any conditions that are attended by cellular stress, such as NDs, it can be
expected that miRNA expression patterns will change, which would be expected in turn to
alter the translation of a large number of different cellular mRNAs.
miRNAs IN THE MAMMALIAN BRAIN
miRNAs are enriched in human and rodents brain: relative to other organs, more miRNAs
are expressed in brain and at somewhat higher levels (4, 6, 9, 114, but see 37,122). Very
high-throughput sequencing experiments have been interpreted to suggest that the number of
miRNAs expressed in human brain is over 1000, although currently only ~550 have been
annotated in all humans (8). It has been speculated that miRNAs and other non-coding
RNAs may serve to act as a “complexity multiplier” to help translate the ~25 000 human
protein-coding genes into the human cerebral cortex with its ~1013 neurons, 1018 synapses
and the staggeringly complex processes of neurodevelopment and neurophysiological
network integration (35,88).
The expression of brain miRNAs alters in the course of brain development. Accordingly,
some miRNAs are relatively enriched during early development in the mammalian brain,
and some are relatively enriched during later development (85,90). These changes may
relate to biochemical cues in cell fate determination, apoptosis and/or cell division
programming (116). Some miRNAs are also relatively enriched in different neuronal nuclei,
and/or different cell populations, including neurons or glia (117; see Figure 2). For example,
it was recently shown that some rat miRNAs are relatively specific to the hippocampus
relative to the rest of rat brain, and another miRNA may be enriched in the substantia nigra
(46,58). Furthermore, some miRNAs are relatively enriched in some neuronal cell
compartments (somatodendritic vs. axonal) (64).
The function of brain miRNAs are evidently not related only to cell fate determination along
developmental lineages. miRNAs may also play important roles in neuroplasticity and in
many other neurobiological functions. These are beyond the scope of this review, and well
discussed previously (61,62). However, it bears repeating that probably most of the
functions for miRNAs in the brain as elsewhere have yet to be discovered. The miRNA
system is adaptable and researchers should be as open-minded as possible in developing
testable hypotheses about physiologically relevant miRNA actions.
miRNAs IN NEURODEGENERATION—AN EXPANDING RESEARCH
CORPUS
The current data that explicitly pertain to miRNAs and neurodegeneration must be
characterized as preliminary, reflecting that our understanding of miRNAs is still in its
infancy. However, recent studies have begun providing important glimpses into the
functions of miRNAs in neuroprotection and neurodegeneration. These studies have been
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performed across a variety of cells and organisms. A table of some studies that include
animal models is provided (Table 1).
With regard to the functions of miRNAs in neuroprotection and NDs, experiments in
invertebrates have provided important data. Research from Nancy Bonini’s laboratory have
shown that miRNAs can play an important role in modulating the nerve cell toxicity of
pathologically altered SCA3 (spinocerebellar ataxia type 3) protein (12,13). Increased
number of polyglutamine repeats in SCA3 is what mediates the human clinical phenotype
(106), and also correlates with cellular toxicity in the fly eye (13). SCA3 polyglutamine
toxicity is greatly potentiated when miRNA pathways are inhibited. A particular miRNA
(ban) is a factor of neuroprotection both in SCA3- and MAPT-related neurodegeneration in
flies (12,13). Also in flies, the miRNA miR-7 has been shown to potentiate stable EGFR
signaling in photoreceptor cells (71). Still another fly miRNA (miR-14) also serves to help
enable appropriate homeostasis in Drosophila eye cells, and particularly to play a role in
adapting to stress (127). Taken together, these studies from different laboratories in flies
demonstrate that animal miRNAs play a neuroprotective role in stress- and ND-relevant
neuroprotection.
In addition to the studies in invertebrates, recent mammalian studies have also suggested a
role for miRNAs in NDs and neuroprotection. Workers in Paul Greengard’s laboratory used
transgenic mice to give support to the hypothesis that miRNA function is critical for
mammalian neuronal survival (and conversely, compromising miRNAs causes
neurodegeneration) (113). In this study, the cerebellar Purkinje cell-specific Pcp2 promoter
was used to drive a Cre recombinase causing the dicer gene (and the production of most
mature miRNAs) to be knocked down beginning in the second week of life with Pcp2 gene
activation. Loss of cerebellar expression of both dicer and most mature miRNAs is followed
by Purkinje cell death and dendritic withering neuropathologically, and an ataxia phenotype
develops in the mice. The authors hypothesize that as dicer down-regulation causes neuronal
cell death, then some human neurodegenerative diseases may be caused by loss of small
regulatory RNAs. As dicer is knocked out in the cerebellum, the authors conclude that their
work may be relevant to spinocerebellar ataxias.
In another important work concerning miRNAs in NDs, research from Asa Abeliovich’s
laboratory indicates that a particular miRNA may play a significant role in PD (58). The
authors show experimentally that miR-133b is relatively highly expressed at the tissue level
in midbrain under normal conditions, but not during PD. Furhthermore, knocking out
miRNAs generally in vivo, or miR-133b by itself in culture, dramatically decreases tyrosine
hydroxylase and dopamine transporter levels in dopaminergic neurons. The data also
support the hypothesis that miR-133b and the paired-like homeodomain transcription factor
PITX3 regulate each other’s expression. This study is important for a number of reasons.
First, it indicates a discrete role for a particular miRNA in dopaminergic function. Second,
previously, no particular miRNA–mRNA pair had been strongly implicated in a prevalent
neurodegenerative disease. In other words, these investigators have provided plausible
molecular neurobiological breakthroughs for both miRNA function and dysfunction. This
study demonstrates also how miRNAs can be an important component of a “downward
spiral” during NDs.
Two other excellent recent papers (79,78) came from Walter Lukiw’s laboratory. DNA
arrays were analysed to evaluate the expression of a subset of 12 miRNAs in the AD
hippocampus in comparison with non-demented controls and fetal brain. The results of the
expression profiling was that miR-9 is elevated in both fetal hippocampus and AD
hippocampus, miR-128a is elevated in AD but neither fetus nor non-demented controls, and
miR-125b shows a trend to be increased in AD that is not statistically significant (78). In a
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second study from the same group (79), cultured human fetal brain-derived primary neural
(HN) cells, which included both astrocytes and neurons, were treated with metal salts, such
as aluminum and iron sulfates that stimulate reactive oxygen species (ROS). The RNA from
HN cells was then compared using the same DNA miRNA array that was used in the study
of AD brains. Remarkably, the HN cells treated using conditions that activate ROS also had
essentially the same changes (increased expression of miR-9, miR-128 and, to a lesser
extent, miR-125b) vs. controls, as were seen in the AD brain in comparison with non-
demented brains. The authors make several inferences from these data. First, these data
provide evidence in support of the hypothesis that ROS influence AD brain through
pathways specifically mediated by miRNAs. Second, miR-125b, which trends higher in both
AD brain and in ROS-treated HN cells, is predicted to target the mRNA of synapsin I and
synapsin II, and thus down-regulation of synapsins in AD may be partially explained by
miR-125b up-regulation (78,79).
Some genes have been associated most strongly with NDs, and it would be interesting to see
how strongly these genes are in turn regulated by miRNAs. Two examples are presented
(Figure 3): beta-amyloid precursor protein and alpha-synuclein, which are important in the
pathogenesis of AD and PD, respectively. An important characteristic of both of these genes
is that studies have shown that the disease phenotypes in humans can be caused solely by
increasing the expression of the genes (50,87). As shown in Figure 3, each of these genes is
also predicted to be the target of multiple miRNAs. These predictions are not validated;
however, they derive from only a single miRNA prediction database and still more miRNAs
could easily target each of these (as well as many other) mRNAs.
Aside from the associations between miRNA changes and “classic” NDs, it is also notable
that miRNAs may play a role in other degenerative brain diseases, including the fragile X
mental retardation syndrome. Fragile X-associated tremor/ataxia syndrome (FXTAS) affects
generally male carriers of expanded triplet CGG repeats on the fragile X mental retardation
1 (FMR1) gene. The polypeptide product of FMR1 is the protein FMRP, which is
effectively silenced during the disease (36,123). Neuropathologically, FXTAS syndrome is
characterized by intranuclear inclusions, white matter changes and atypical appearing
astrocytes profiles (40). Numerous lines of evidence suggest that FMRP interacts with the
miRNA machinery, including miRNAs themselves (22,33,52,55,98). One hypothesis for the
etiology of FMR is that a miRNA derived from the triplet repeat expansion in FMR1’s
3′UTR mediates a methylation event that inhibits profoundly the transcription of FMR1
(54,98). This hypothesis has been supported experimentally (74).
miRNAs IN NEURODEGENERATION—THEORETICAL ASPECTS AND
QUESTIONS FOR THE FUTURE
Most of the details of how miRNAs participate in neurodegeneration have yet to be worked
out. Hence, at this point, one may consider that the current research corpus is mostly a
platform for future gains. Figure 4 shows some of the possibilities related to the interactions
between miRNAs and NDs. Here are questions that may merit some reflection:
i. Neurons are distinguished geometrically by their exceptionally asymmetric shape,
with complicated functions requiring protein translation long distances—in some
places, many centimeters—from the cell nucleus. Do miRNAs play a role in
localized control of mRNA translation, and if so, does perturbation of that localized
translational control contribute to NDs?
ii. If RNAs are altered in NDs, are miRNAs altered also, and does ND-related miRNA
alterations (eg, oxidation) alter biochemical function?
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iii. miRNAs are implicated in cell fate determination, apoptosis, cell division and
stress, all of which are pathways thought to be aberrantly up-regulated in ND
brains. Could the miRNA-related pathways relevant to earlier development be
pathogenetic in the adult brain milieu?
iv. Do risk factors for NDs (eg, the Apolipoprotein epsilon 4 allele) affect miRNA
brain expression?
v. To what extent are genes that are allelic for NDs, and for increased or decreased
risk for NDs, target for miRNA regulation?
vi. Is RNA editing of miRNAs changed in NDs?
vii. What are the prospects for using miRNA-related biochemistry for ND therapeutics?
CONCLUSIONS
The regulation of human genomic expression is tremendously complex—it has to be in order
to provide an information template for the human brain. We have only begun to understand
the function of non-coding RNAs, such as miRNAs, in providing a complexity multiplier for
the genome in the human CNS. It is hoped that research into the normal biochemical brain
processes will dovetail with a better understanding of the pathological processes that these
same molecules and pathways play. Tantalizing preliminary evidence suggests that miRNAs
may play an important role in NDs.
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Figure 1.
In the mammalian brain as elsewhere, miRNAs subserve multiple fundamental biological
roles. Many miRNAs are thought to interact with thousands of different targets. Post-
transcriptional RNA editing may change mRNA target specifity. References for the different
hypothesized functions of miRNAs are given in the text.
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Figure 2. In situ hybridization (ISH) from normal human brains for miRNAs gives an idea of
how miRNAs are expressed in neuroanatomical areas that are vulnerable to NDs
A–C show hippocampus. A,B shows miRNAs (miR-124 and miR-320) that are expressed
predominantly in neurons. By contrast, let-7b is expressed in both neurons and glia, so cells
outside the neuronal layers (such as the molecular layer, pink star, of the dentate granules,
dg) are stained. D shows that cells of the superficial layer of entorhinal cortex are also
stained avidly using a miR-124 probe. In the substantia nigra, miR-320 labels the pigment-
containing cells (E), but miR-107 only labels them barely if at all (F). Scale bars: A–D =
500 μM; E = 125 μM; F = 62.5 μM. ISH was performed according to the protocol
previously described (89) except fixed brain was cut with a freezing microtome.
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Figure 3.
Not only does a given miRNA recognize many mRNA targets, but the 3′ untranslated region
(3′UTR) of many mRNAs are also the potential targets for many different miRNAs. Here
are two examples that are relevant to NDs, the beta-amyloid precursor protein (APP) and
alpha-synuclein (SNCA). miRNA target predictions are from the miRBASE registry
(http://microrna.sanger.ac.uk/targets/v4/), and have not been validated. APP is predicted to
be recognized by the products of 41 different miRNA genes, and SNCA is predicted to be
recognized by that of 12.
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Figure 4.
A schematic diagram about some roles miRNAs may play in NDs. The brains of persons at
risk for NDs are subjected to chronic stimuli that can perturb specific and/or global miRNA
expression. Either the aberrant stimulation or inhibition of miRNA expression may be
associated with pathways involved in NDs or neuroprotection.
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Table 1
Experimental system Study relating miRNAs and ND Notes References
Fly eye Dicer knock-down potentiates neurodegeneration in
response to SCA3 and MAPT toxicity
Implicates miRNAs in
neuroprotection from ND-related
neurotoxicity
(12,13)
Mouse cerebellum Dicer knock-down leads to cerebellar
neurodegeneration and ataxia
Analagies are drawn to
spinocerebellar ataxia
(113)
Mouse and human substantia
nigra
miR-133b is down-regulated in Parkinson’s patients
and may play a role in dopaminergic neuronal
development
An important connection between
novel new roles for miRNA function
as well as ND-related dysfunction
(58)
Human brain and primary
human neural cultures
A subset of miRNAs is increased in AD hippocampus
and also in cell culture due to reactive oxygen species
such as aluminum and iron sulfate
Draws a first direct link between
oxidative stress, miRNAs, and NDs
(78,79)
Abbreviations: AD = Alzheimer’s disease; miRNA = microRNA; ND = neurodegenerative diseases; SCA3 = spinocerebellar ataxia type 3.
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